PL3030557T3 - Nowe pochodne ftalazynonu i ich sposób wytwarzania - Google Patents

Nowe pochodne ftalazynonu i ich sposób wytwarzania

Info

Publication number
PL3030557T3
PL3030557T3 PL14843941.7T PL14843941T PL3030557T3 PL 3030557 T3 PL3030557 T3 PL 3030557T3 PL 14843941 T PL14843941 T PL 14843941T PL 3030557 T3 PL3030557 T3 PL 3030557T3
Authority
PL
Poland
Prior art keywords
novel
manufacturing process
phtalazinone
derivatives
phtalazinone derivatives
Prior art date
Application number
PL14843941.7T
Other languages
English (en)
Polish (pl)
Inventor
Jae-Hoon Kang
Hong-Sub Lee
Yoon-Suk Lee
Joon-Tae Park
Kyung-Mi An
Jin-Ah Jeong
Kyung-Sun Kim
Jeong-Geun Kim
Chang-Hee Hong
Sun-Young Park
Dong-Keun Song
Yong-Don YUN
Original Assignee
Idience Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idience Co., Ltd. filed Critical Idience Co., Ltd.
Publication of PL3030557T3 publication Critical patent/PL3030557T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PL14843941.7T 2013-09-13 2014-09-12 Nowe pochodne ftalazynonu i ich sposób wytwarzania PL3030557T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20130110170 2013-09-13
KR1020140120152A KR101670126B1 (ko) 2013-09-13 2014-09-11 신규 프탈라지논 유도체 및 그 제조방법
PCT/KR2014/008523 WO2015037939A1 (en) 2013-09-13 2014-09-12 A novel phtalazinone derivatives and manufacturing process thereof

Publications (1)

Publication Number Publication Date
PL3030557T3 true PL3030557T3 (pl) 2023-10-16

Family

ID=53024930

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14843941.7T PL3030557T3 (pl) 2013-09-13 2014-09-12 Nowe pochodne ftalazynonu i ich sposób wytwarzania

Country Status (25)

Country Link
US (3) US9682973B2 (enExample)
EP (1) EP3030557B1 (enExample)
JP (1) JP6180643B2 (enExample)
KR (1) KR101670126B1 (enExample)
CN (1) CN105793248B (enExample)
AU (1) AU2014319132C1 (enExample)
BR (1) BR112016004979B1 (enExample)
CA (1) CA2923614C (enExample)
DK (1) DK3030557T3 (enExample)
ES (1) ES2953834T3 (enExample)
FI (1) FI3030557T3 (enExample)
HR (1) HRP20230998T1 (enExample)
HU (1) HUE062770T2 (enExample)
IL (1) IL244548B (enExample)
LT (1) LT3030557T (enExample)
MX (1) MX379467B (enExample)
MY (1) MY195343A (enExample)
PL (1) PL3030557T3 (enExample)
PT (1) PT3030557T (enExample)
RS (1) RS64477B1 (enExample)
RU (1) RU2636585C2 (enExample)
SG (1) SG11201600549TA (enExample)
SI (1) SI3030557T1 (enExample)
SM (1) SMT202300268T1 (enExample)
WO (1) WO2015037939A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101670126B1 (ko) * 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
WO2019169156A1 (en) 2018-02-28 2019-09-06 The Trustees Of The University Of Pennsylvania Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents
JP7626783B2 (ja) * 2020-04-21 2025-02-07 アイディーエンス カンパニー リミテッド フタラジノン誘導体及びその中間体を調製するプロセス
MY209003A (en) * 2020-04-21 2025-06-16 Idience Co Ltd Crystalline forms of phthalazinone compound
CN115515939B (zh) * 2020-05-08 2024-12-13 谛希诺生物科技有限公司 具有抑制外核苷酸焦磷酸酶-磷酸二酯酶的活性的新型酞嗪衍生物及它们的用途
US12059419B2 (en) * 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
WO2022087422A1 (en) * 2020-10-22 2022-04-28 Chulalongkorn University Pyrrolidine-3-carboxamide derivatives and related uses
KR20220125183A (ko) 2021-03-04 2022-09-14 아이디언스 주식회사 Parp 억제제에 내성을 가진 환자군의 암 치료제로서의 프탈라지논 유도체의 항암제 용도
WO2022186649A1 (ko) * 2021-03-04 2022-09-09 아이디언스 주식회사 Parp 억제제에 내성을 가진 환자군의 암 치료제로서의 프탈라지논 유도체의 항암제 용도
KR20240016319A (ko) * 2021-06-02 2024-02-06 아이디언스 주식회사 프탈라지논 유도체를 이용한 장애 치료 방법
WO2023144626A1 (en) * 2022-01-25 2023-08-03 Idience Co., Ltd. Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug
WO2024025389A1 (ko) * 2022-07-29 2024-02-01 아이디언스 주식회사 프탈라지논 유도체의 중간체의 제조방법
CN117229260B (zh) * 2023-11-13 2024-02-27 中国药科大学 DNA聚合酶θ与聚ADP核糖聚合酶1双靶点抑制剂及其制备方法和医药用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228960B1 (hu) 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok
AU2003229953A1 (en) 2002-04-30 2003-11-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1633724B1 (en) 2003-03-12 2011-05-04 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2007266840B2 (en) 2006-05-31 2012-09-20 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrrolo[1,2-A]pyrazin-1(2H)-one and pyrrolo[1,2-D][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase(PARP)
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
PL2120579T3 (pl) 2006-12-28 2014-04-30 Abbvie Inc Inhibitory polimerazy poli(ADP-rybozy)
CN101030723A (zh) 2007-04-04 2007-09-05 钟志华 电磁变相发动机
KR101641596B1 (ko) 2007-11-15 2016-07-21 엠에스디 이탈리아 에스.알.엘. Parp 억제제로서의 피리다지논 유도체
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
US8871765B2 (en) 2010-07-27 2014-10-28 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372706A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372698A (zh) 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
US8999985B2 (en) * 2010-12-02 2015-04-07 Shanghai De Novo Pharmatech Co Ltd. Substituted phthalazin-1(2H)-ones, preparation processes and medical uses thereof
CN102485721B (zh) 2010-12-03 2015-12-09 曹亚 取代的2,3-二氮杂萘酮化合物及其用途
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
KR101670126B1 (ko) * 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법

Also Published As

Publication number Publication date
EP3030557A1 (en) 2016-06-15
US20160222003A1 (en) 2016-08-04
KR101670126B1 (ko) 2016-10-27
HRP20230998T1 (hr) 2023-12-08
CA2923614A1 (en) 2015-03-19
CN105793248B (zh) 2019-08-16
MY195343A (en) 2023-01-13
USRE49338E1 (en) 2022-12-20
JP2016534143A (ja) 2016-11-04
LT3030557T (lt) 2023-09-11
EP3030557A4 (en) 2017-03-22
KR20150031196A (ko) 2015-03-23
SG11201600549TA (en) 2016-02-26
US9682973B2 (en) 2017-06-20
US20170182045A1 (en) 2017-06-29
CA2923614C (en) 2017-06-27
WO2015037939A1 (en) 2015-03-19
HUE062770T2 (hu) 2023-12-28
PT3030557T (pt) 2023-09-04
MX2016002998A (es) 2016-06-02
IL244548A0 (en) 2016-04-21
SI3030557T1 (sl) 2023-11-30
SMT202300268T1 (it) 2023-09-06
EP3030557B1 (en) 2023-05-31
MX379467B (es) 2025-03-10
AU2014319132A1 (en) 2016-02-11
BR112016004979A2 (pt) 2020-05-12
CN105793248A (zh) 2016-07-20
BR112016004979B1 (pt) 2023-01-10
JP6180643B2 (ja) 2017-08-16
FI3030557T3 (fi) 2023-08-21
DK3030557T3 (da) 2023-09-04
RS64477B1 (sr) 2023-09-29
US9844550B2 (en) 2017-12-19
RU2636585C2 (ru) 2017-11-24
AU2014319132C1 (en) 2020-09-03
IL244548B (en) 2020-10-29
ES2953834T3 (es) 2023-11-16
HK1224280A1 (zh) 2017-08-18
RU2016108038A (ru) 2017-09-07
AU2014319132B2 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
GB2520596B (en) Manufacturing method
GB2511914B (en) Object production
IL244548A0 (en) New derivatives of phthalazinone and a method for their production
ZA201506050B (en) Vortioxetine manufacturing process
IL240748A0 (en) Methods for generating adenovirus
GB201414400D0 (en) Object production
GB201313915D0 (en) Process
GB201322303D0 (en) Production process
GB201307327D0 (en) Process
GB201302441D0 (en) Process
ZA201602318B (en) Can end production
GB201307951D0 (en) Process
GB201302233D0 (en) Forming a ceramic product
GB201300073D0 (en) Process
IL243649A0 (en) Lollipop and process for its production
GB201306986D0 (en) Can production process
GB201303604D0 (en) Manufacturing process
GB201322300D0 (en) Method of manufacturing a cylindrical article
GB201317272D0 (en) Object production
GB201314513D0 (en) Object production
GB201300852D0 (en) Object production
GB201312961D0 (en) Production Plan
GB201319311D0 (en) A decorative article
AU2013902477A0 (en) A package and process
GB201317040D0 (en) A smoking article